 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: ZEPOSIA (ozanimod) |
|
***************************************************** |
|
#Post#: 2162-------------------------------------------------- |
|
(Abst.) Efficacy and safety of ozanimod in MS |
|
By: agate Date: July 26, 2018, 7:51 pm |
|
--------------------------------------------------------- |
|
"Efficacy and safety of ozanimod in multiple sclerosis: |
|
Dose-blinded extension of a randomized Phase II study" by from |
|
PubMed, July 26, 2018: |
|
https://www.ncbi.nlm.nih.gov/pubmed/30043658 |
|
#Post#: 2644-------------------------------------------------- |
|
(Abst.) Ozanimod vs. IFN beta-1a in Phase 3 RADIANCE trial |
|
By: agate Date: September 8, 2019, 8:13 pm |
|
--------------------------------------------------------- |
|
Abstract of an article in The Lancet (September 3, 2019), |
|
"Safety and efficacy of ozanimod vs. interferon beta-1a in |
|
relapsing multiple sclerosis (RADIANCE): A multicentre, |
|
randomised, 24-month, phase 3 trial": |
|
https://www.ncbi.nlm.nih.gov/pubmed/31492652 |
|
#Post#: 2645-------------------------------------------------- |
|
(Abst.) Ozanimod vs. IFN beta-1a in Phase 3 SUNBEAM trial |
|
By: agate Date: September 8, 2019, 8:17 pm |
|
--------------------------------------------------------- |
|
Abstract of an article in The Lancet (September 3, 2019) about a |
|
different trial (see previous post) involving ozanimod and |
|
interferon beta-1a--"Safety and efficacy of ozanimod vs. |
|
interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A |
|
multicentre, randomised, minimum 12-month, phase 3 trial": |
|
https://www.ncbi.nlm.nih.gov/pubmed/31492651 |
|
***************************************************** |
